Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comDescription:
This study will look at whether it is practical and safe to give Lutathera directly into an artery of the liver (hepatic intraarterial infusion). The researchers will compare the effects of hepatic intraarterial infusion in the liver with the effects of the standard approach (intravenous infusion in the arm). The researchers will also determine whether Lutathera is effective against participants' cancer.
Sponsor:
Memorial Sloan Kettering Cancer Center
Phase:
Early Phase 1
Government Study Link:
NCT04544098 - Click here to see study onClinicalTrials.gov
Help us improve your experience